Takeda Completes Acquisition of URL Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda Completes Acquisition of URL Pharma


ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals USA, jointly announced that the acquisition of URL Pharma for an upfront payment of $800 million has been completed. The deal also includes an agreement for future performance-based payments.

Takeda will immediately assume responsibility for the marketing and promotion of Colcrys (colchicine), URL Pharma’s leading product, which is used for the treatment and prevention of flares associated with gout. The addition of Colcrys to the company’s portfolio complements Takeda’s position in the gout marketplace with Uloric (febuxostat), used to lower blood uric acid levels in adults with gout. Douglas Cole, president of Takeda Pharmaceuticals USA said in the press release, “This commitment allows us to broaden our focus for patients by providing multiple therapeutic offerings for gout, which affects more than eight million Americans.”

The company expects that the acquisition will result in an immediate increase in revenue with estimated fiscal year 2012 net sales of more than $550 million and also expects continued growth of Colcrys sales throughout the product’s lifecycle.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here